Summary
Delcath Systems (DCTH) shows strong technical buy signals, with a 53.41% gain since 1/25 and a 271.33% gain in the last year.
The company focuses on liver cancer treatments, with its leading product HEPZATO KIT and ongoing FOCUS clinical trial for metastatic uveal melanoma.
Barchart indicators highlight 100% technical buy signals, a Weighted Alpha of 149.43+, and the stock trading above its 20, 50, and 100-day moving averages.
Analysts give strong buy ratings with a price target consensus of $22, while MorningStar considers the stock 50% overvalued.
The Chart of the Day belongs to the medical device company Delcath Systems (DCTH) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 1/25 the stock gained 53.41%.
DCTH Price vs Daily Moving Averages:
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.
Barchart Technical Indicators:
- 100% technical buy signals
- 149.43+ Weighted Alpha
- 271.33% gain in the last year
- Trend Seeker buy signal
- .87 - 60 month Beta
- Above its 20, 50 and 100 day moving averages
- 12 new highs and up 41.52% in the last month
- Relative Strength Index 78.48%
- Technical support level at $14.74
- Recently traded at $16.15 with 50 day moving average of $11.70
Fundamental Factors:
- Market Cap $486 million
- Revenue expected to grow 1,694.67% this year and another 109.49% next year
- Earnings estimated to increase 74.69% this year and an additional 94.35% next year
Analysts and Investor Sentiment -- I don't buy stocks because everyone else is buying but I do realize that if major firms and investors are dumping a stock it's hard to make money swimming against the tide:
- Wall Street analysts issued 4 strong buy and 2 buy opinions on the stock
- Their price target are between $20 and $25 with a consensus of $22 for a 36% gain
- MorningStar thinks the stock is 50% over valued
- 15,020 investors monitor the stock on Seeking Alpha
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis.
I really enjoy and solicit your feedback. If you find Chart of the Day helpful please click the envelope in the upper right corner and leave a comment. Constructive criticism is also appreciated.
On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
